About Us
Our Business
Investors
Media
Community
Sustainability
Careers
Contact
Menu
India
USA
UK
South Africa
Australia
Philippines
Germany
Netherlands
Mexico
Brazil
Canada
Switzerland
Close
About Us
Overview
The Lupin Story
Our Purpose
Our Values
Our Leadership
Ethics, Compliance and Governance
Global Presence
Our Manufacturing Approach
Quality in Action
Our Science
Awards and Recognitions
Our Business
Overview
Global Generics
Emerging Markets
India
Specialty and Innovation
Biosimilars
Our Adjacencies
Investors
Overview
Financials
Reports and Filings
Committees of the Board
Code of Conduct
Policies
Shareholder Information
Memorandum and Articles of Association
Employee Stock Option Schemes
News and Events
Business Responsibility
Analyst Coverage
Investor FAQs
Disclosure under Regulation 46 of SEBI (LODR) Regulations, 2015
Media
Overview
Press Releases
Media Coverage
Perspectives
Media Kit
Community
Sustainability
Overview
ESG Framework
ESG Goals and Progress
Key Highlights
ESG Ratings
ESG Governance
Careers
About Us
Our Business
Investors
Media
Community
Sustainability
Careers
Overview
The Lupin Story
Our Purpose
Our Values
Our Leadership
Ethics, Compliance and Governance
Global Presence
Our Manufacturing Approach
Quality in Action
Our Science
Awards and Recognitions
+91 22 6640 2323
info@lupin.com
News and
Events
Press Releases
Explore
February 4, 2026
Press
Release
Lupin Launches Topiramate
Extended-Release Capsules in
the United
States
February 2, 2026
Press
Release
Lupin and TB Alliance Join
Forces to Advance Telacebec for
the Treatment of Tuberculosis and
Other Mycobacterial
February 2, 2026
Press
Release
Lupin Launches
Dasatinib Tablets
in the
United
January 23, 2026
Press
Release
Lupin Receives Highest ESG
Rating from CDP for
Climate Change and Water
Security
January 21, 2026
Press
Release
Lupin and Galenicum Sign
License and Supply Agreement
for Semaglutide in 23
Countries
December 29, 2025
Press
Release
Lupin Signs Exclusive Licensing
Agreement with Gan &
Lee Pharmaceuticals for novel
GLP-1 receptor
December 18, 2025
Press
Release
Lupin Signs Exclusive Licensing
Agreement with Neopharmed for
Gastroenterology Brand Plasil® in
the Philippines and
December 17, 2025
Press
Release
Lupin Receives
Positive CHMP
Opinion for
Biosimilar
December 16, 2025
Press
Release
Lupin Receives EIR from
US FDA for
its Nagpur Injectable
Facility
December 15, 2025
Press
Release
Lupin Secures
SBTi Validation
for Emission
Reduction
Previous
Next
Annual General Meeting
42nd Annual General Meeting – Aug 2, 2024
42nd Annual General Meeting Transcript
41st Annual General Meeting – August 3, 2023
40th Annual General Meeting — August 3, 2022
39th Annual General Meeting — August 11, 2021
Events
November 6, 2025
Q2 FY2026 Board meeting
August 11, 2025
43rd Annual General Meeting
Presentations
Lupin’s acquisition of VISUfarma
Download PDF
Vinita Gupta at the JP Morgan Healthcare Conference Jan 10 2023
Download PDF
Vinita Gupta at the JP Morgan Healthcare Conference Jan 12 2022
Download PDF
Vinita Gupta at the JP Morgan Healthcare Conference Jan 12 2021
JP Morgan Healthcare Conference
Download PDF
JP Morgan Healthcare Conference 2020
Download PDF
JP Morgan Healthcare Conference 2019
Download PDF
Investor
Contacts
Shareholder Services
investorservices@lupin.com
investor.helpdesk@in.mpms.mufg.com
Investor Relations
InvestorRelations@lupin.com
Subscribe for
Investor updates
I agree and accept the
Privacy Policy
and the
Terms of Use
of this website
Submit
Product Finder
Investor News, Events and Updates - Lupin
